anmelden
Novartis Aktie
124,66
EUR
-1,16
EUR
-0,92
%
124,68
EUR
-1,32
EUR
-1,05
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Marktkap. 233,71 Mrd. EUR
KGV 18,30 Div. Rendite 3,38%WKN 904278
ISIN CH0012005267
Symbol NVSEF
AI Analyse
Werbung
Novartis Aktie Analyse
| 19.07.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 19.07.17 | Novartis Hold | Deutsche Bank AG | |
| 18.07.17 | Novartis Outperform | Bernstein Research | |
| 18.07.17 | Novartis Hold | S&P Capital IQ | |
| 18.07.17 | Novartis Neutral | UBS AG | |
| 17.07.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 14.07.17 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 14.07.17 | Novartis Neutral | Goldman Sachs Group Inc. | |
|
Werbung
|
|||
| 10.07.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 07.07.17 | Novartis Hold | Deutsche Bank AG | |
| 05.07.17 | Novartis Underperform | Credit Suisse Group | |
| 04.07.17 | Novartis buy | Kepler Cheuvreux | |
| 23.06.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 23.06.17 | Novartis Equal weight | Barclays Capital | |
| 23.06.17 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 23.06.17 | Novartis buy | Jefferies & Company Inc. | |
| 21.06.17 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 21.06.17 | Novartis Hold | Deutsche Bank AG | |
| 21.06.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 21.06.17 | Novartis buy | HSBC | |
| 16.06.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 14.06.17 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 08.06.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 06.06.17 | Novartis Underweight | Morgan Stanley | |
| 02.06.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 02.06.17 | Novartis Underweight | Barclays Capital | |
| 02.06.17 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 01.06.17 | Novartis buy | Jefferies & Company Inc. | |
| 24.05.17 | Novartis Neutral | UBS AG | |
| 19.05.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 17.05.17 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 12.05.17 | Novartis buy | Jefferies & Company Inc. | |
| 12.05.17 | Novartis Underweight | Morgan Stanley | |
| 26.04.17 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 26.04.17 | Novartis Underweight | Morgan Stanley | |
| 26.04.17 | Novartis Hold | Deutsche Bank AG | |
| 25.04.17 | Novartis Hold | S&P Capital IQ | |
| 21.04.17 | Novartis Neutral | UBS AG | |
| 19.04.17 | Novartis Underweight | Morgan Stanley | |
| 18.04.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 11.04.17 | Novartis Hold | Deutsche Bank AG | |
| 06.04.17 | Novartis Neutral | UBS AG | |
| 23.03.17 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 23.03.17 | Novartis buy | Kepler Cheuvreux | |
| 23.03.17 | Novartis buy | Société Générale Group S.A. (SG) | |
| 23.03.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 23.03.17 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 17.03.17 | Novartis Hold | Deutsche Bank AG | |
| 15.03.17 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 14.03.17 | Novartis Neutral | JP Morgan Chase & Co. | |
Werbung
Werbung
